HLA-B*5901 is strongly associated with methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Flach AJ, Smith RE, Flaunfelder FT: Stevens–Johnson syndrome associated with methazolamide treatment reported in two Japanese–American women. Ophthalmology102(11),1677–1680 (1995).▪ First case report to introduce methazolamide-induced Stevens–Johnson syndrome (SJS).
  Medline CASGoogle Scholar
• 2  Shirato S, Kagaya F, Suzuki Y, Joukou S: Stevens–Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol.115(4),550–553 (1997).▪▪ First case report describing the association between methazolamide-induced SJS and the HLA-B59 serotype.
  Medline CASGoogle Scholar
• 3  Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N. Engl. J. Med.331(19),1272–1285 (1994).
  Medline CASGoogle Scholar
• 4  Cotter JB: Methazolamide-induced Stevens–Johnson syndrome: a warning! Arch. Ophthalmol.116(1),117 (1998).
  Medline CASGoogle Scholar
• 5  Park YJ, Moon JI, Park CK: Three cases of Stevens–Johnson syndrome associated with methazolamide treatment. J. Korean Ophthalmol. Soc.40(2),613–618 (1999).
  Google Scholar
• 6  Moon JI, Seo JH, Park CK: Association of HLA type with Stevens–Johnson syndrome induced by methazolamide treatment. J. Korean Ophthalmol. Soc.41(10),2241–2246 (2000).
  Google Scholar
• 7  Ahn EY, Lee JB, Lee SC, Won YH: Four cases of Stevens–Johnson syndrome associated with methazolamide treatment. Korean Dermatol.38(6),798–801 (2000).
  Google Scholar
• 8  Sung KH, Jwong Y, Choi HU, Lee SK: Two cases of HLA-B59(+) Stevens–Johnson syndrome (SJS)–toxic epidermal necrolysis (TEN) associated with methazolamide treatment. Korean Dermatol.43(4),561–563 (2005).
  Google Scholar
• 9  Lee KW, Oh HD, Lee C, Yang SY: Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens65(5),437–447 (2005).▪ The HLA class I and class II allelic and haplotype frequency was determined in the Korean general population. These data were used as the control in our study.
  Medline CASGoogle Scholar
• 10  Saito S, Ota S, Yamada E, Inoko H, Ota M: Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens56(6),522–529 (2000).
  Medline CASGoogle Scholar
• 11  Roujeau JC: The spectrum of Stevens–Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J. Invest. Dermatol.102(6),S28–S30 (1994).
  Medline CASGoogle Scholar
• 12  Seo YS, Chang KC, Chang MH: Methazolamide-induced Stevens–Johnson Syndrome. J. Korean Ophthalmol. Soc.50(12),1881–1886 (2009).
  Google Scholar
• 13  Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res.16(3),1215 (1988).
  Medline CASGoogle Scholar
• 14  French LE: Toxic epidermal necrolysis and Stevens–Johnson syndrome: our current understanding. Allergol. Int.55(1),9–16 (2006).
  MedlineGoogle Scholar
• 15  Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME: Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun. Rev.7(8),598–605 (2008).
  Medline CASGoogle Scholar
• 16  Pirmohamed M: Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J.8(1),E20–E26 (2006).
  Medline CASGoogle Scholar
• 17  Chung WH, Hung SI, Chen YT: Human leukocyte antigens and drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol.7(4),317–323 (2007).▪ Review discussing recent evidence, drug-/ethnicity-/phenotype-specific features, pathogenetic mechanisms and the clinical implications of HLA associations with drug hypersensitivity.
  Medline CASGoogle Scholar
• 18  Sheffield LJ, Phillimore HE: Clinical use of pharmacogenomic tests in 2009. Clin. Biochem. Rev.30(2),55–65 (2009).
  MedlineGoogle Scholar
• 19  Chung WH, Hung SI, Hong HS et al.: A marker for Stevens–Johnson syndrome. Nature428(6982),486 (2004).▪▪ Case–control study that first demonstrated the striking association between HLA-B*1502 and carbamazepine-induced SJS.
  Medline CASGoogle Scholar
• 20  Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics7(6),813–818 (2006).
  CASGoogle Scholar
• 21  Kaniwa N, Saito Y, Aihara M et al.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics9(11),1617–1622 (2008).
  CASGoogle Scholar
• 22  Lee JH, Lee SJ, Kim YH: A case of Stevens–Johnson syndrome after acetazolamide use. J. Korean Ophthalmol. Soc.39(1),216–220 (1998).
  Google Scholar
• 23  Ha JH, Song JY, Kim HO, Kim JW: A case of Stevens–Johnson syndrome caused by acetazolamide. Korean J. Dermatol.41(2),248–250 (2003).
  Google Scholar
• 24  Kim JW, Shin SY: Toxic epidermal necrolysis and Stevens–Johnson syndrome caused by topical ophthalmic use of dorzolamide. Korean J. Dermatol.47(3),317–321 (2009).
  Google Scholar
• 25  Chun JS, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC: Toxic epidermal necrolysis induced by the topical carbonic anhydrase inhibitors brinzolamide and dorzolamide. Ann. Dermatol.20(4),260–262 (2008).
  MedlineGoogle Scholar
• 26  Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch. Dermatol.123(9),1171–1173 (1987).
  Medline CASGoogle Scholar
• 27  Lonjou C, Borot N, Sekula P et al.: A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics.18(2),99–107 (2008).
  Medline CASGoogle Scholar
• 28  Slatore CG, Tilles SA: Sulfonamide hypersensitivity. Immunol. Allergy Clin. North Am.24(3),477–490 (2004).
  MedlineGoogle Scholar
• 29  Brackett CC, Singh H, Block JH: Likelihood and mechanisms of crossallergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy24(7),856–870 (2004).
  Medline CASGoogle Scholar
• 30  Monnet D, Brézin AP: Birdshot chorioretinopathy. Curr. Opin. Ophthalmol.17(6),545–550 (2006).
  MedlineGoogle Scholar
• 31  Martin TM, Kurz DE, Rosenbaum JT: Genetics of uveitis. Ophthalmol. Clin. North Am.16(4),555–565 (2003).
  MedlineGoogle Scholar